<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>AVA - Type 1 Diabetes Research Updates</title>
  <meta name="description" content="Latest breakthroughs in Type 1 Diabetes research">
  <style>
    * { margin: 0; padding: 0; box-sizing: border-box; }
    body {
      font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Arial, sans-serif;
      background: linear-gradient(135deg, #1e3c72 0%, #2a5298 50%, #7e8ba3 100%);
      min-height: 100vh;
      padding: 20px;
      line-height: 1.6;
    }
    .container { max-width: 1200px; margin: 0 auto; }
    .hero {
      background: linear-gradient(135deg, #ffffff 0%, #f8fafc 100%);
      border-radius: 24px;
      padding: 60px 40px;
      margin-bottom: 40px;
      box-shadow: 0 20px 60px rgba(0,0,0,0.15);
      text-align: center;
      position: relative;
      overflow: hidden;
    }
    .hero::before {
      content: '';
      position: absolute;
      top: 0;
      left: 0;
      right: 0;
      height: 6px;
      background: linear-gradient(90deg, #1E90FF 0%, #4FB3FF 50%, #1E90FF 100%);
    }
    .logo { width: 220px; height: auto; margin-bottom: 30px; filter: drop-shadow(0 4px 12px rgba(30, 144, 255, 0.2)); }
    h1 { color: #1f2937; font-size: 3em; font-weight: 700; margin-bottom: 20px; line-height: 1.2; }
    .tagline { color: #6b7280; font-size: 1.4em; margin-bottom: 30px; }
    .mission {
      background: linear-gradient(135deg, #1e3c72 0%, #2a5298 50%, #7e8ba3 100%);
      border-radius: 20px;
      padding: 40px;
      margin-bottom: 40px;
      box-shadow: 0 8px 30px rgba(0,0,0,0.15);
    }
    .mission h2 { color: white; font-size: 2em; margin-bottom: 20px; text-align: center; }
    .mission p { color: rgba(255,255,255,0.9); font-size: 1.15em; line-height: 1.8; text-align: center; max-width: 800px; margin: 0 auto 20px; }
    .stats {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
      gap: 25px;
      margin-bottom: 40px;
    }
    .stat-card {
      background: linear-gradient(135deg, #1e3c72 0%, #2a5298 50%, #7e8ba3 100%);
      padding: 30px;
      border-radius: 16px;
      text-align: center;
      box-shadow: 0 8px 24px rgba(0,0,0,0.15);
      border: 2px solid rgba(255,255,255,0.2);
      transition: all 0.3s;
      color: white;
    }
    .stat-card:hover { transform: translateY(-5px); box-shadow: 0 15px 40px rgba(0,0,0,0.25); border-color: rgba(255,255,255,0.4); }
    .stat-number { font-size: 3em; font-weight: 700; color: #fbbf24; margin-bottom: 10px; }
    .stat-label { color: rgba(255,255,255,0.9); font-size: 1.1em; font-weight: 600; }
    .email-signup {
      background: linear-gradient(135deg, #1E90FF 0%, #4FB3FF 100%);
      border-radius: 20px;
      padding: 50px 40px;
      margin-bottom: 40px;
      box-shadow: 0 15px 50px rgba(30, 144, 255, 0.3);
      text-align: center;
      color: white;
    }
    .email-signup h2 { font-size: 2.2em; margin-bottom: 15px; }
    .email-signup p { font-size: 1.2em; margin-bottom: 30px; opacity: 0.95; }
    .signup-form { display: flex; gap: 15px; max-width: 600px; margin: 0 auto; flex-wrap: wrap; justify-content: center; }
    .signup-form input {
      flex: 1;
      min-width: 250px;
      padding: 16px 24px;
      border: none;
      border-radius: 12px;
      font-size: 16px;
      box-shadow: 0 4px 12px rgba(0,0,0,0.1);
    }
    .signup-form button {
      padding: 16px 40px;
      background: white;
      color: #1E90FF;
      border: none;
      border-radius: 12px;
      font-size: 16px;
      font-weight: 700;
      cursor: pointer;
      transition: all 0.3s;
      box-shadow: 0 4px 12px rgba(0,0,0,0.1);
    }
    .signup-form button:hover { transform: translateY(-2px); box-shadow: 0 8px 20px rgba(0,0,0,0.2); }
    .reports {
      background: linear-gradient(135deg, #1e3c72 0%, #2a5298 50%, #7e8ba3 100%);
      border-radius: 20px;
      padding: 40px;
      margin-bottom: 40px;
      box-shadow: 0 8px 30px rgba(0,0,0,0.15);
    }
    .reports h2 { color: white; font-size: 2em; margin-bottom: 30px; text-align: center; }
    .report-list { display: grid; gap: 20px; }
    .report-item {
      display: flex;
      align-items: center;
      gap: 20px;
      padding: 25px;
      background: rgba(255,255,255,0.1);
      border-radius: 12px;
      transition: all 0.3s;
      text-decoration: none;
      color: inherit;
      border: 1px solid rgba(255,255,255,0.2);
    }
    .report-item:hover { background: rgba(255,255,255,0.2); border-color: #fbbf24; transform: translateX(5px); }
    .report-date { background: #fbbf24; color: #1f2937; padding: 15px; border-radius: 10px; text-align: center; min-width: 80px; font-weight: 700; }
    .report-date .day { font-size: 2em; display: block; line-height: 1; }
    .report-date .month { font-size: 0.9em; opacity: 0.9; }
    .report-info { flex: 1; color: white; }
    .report-title { font-size: 1.3em; font-weight: 700; color: white; margin-bottom: 5px; }
    .report-desc { color: rgba(255,255,255,0.8); }
    
    /* Trials Section Styles */
    .trials {
      background: white;
      border-radius: 20px;
      padding: 40px;
      margin-bottom: 40px;
      box-shadow: 0 8px 30px rgba(0,0,0,0.08);
      border-top: 6px solid #dc2626;
    }
    .trials h2 { 
      color: #dc2626; 
      font-size: 2em; 
      margin-bottom: 30px; 
      text-align: center; 
      display: flex;
      align-items: center;
      justify-content: center;
      gap: 10px;
    }
    .trials h2::before {
      content: "ðŸ”¬";
      font-size: 1.2em;
    }
    .trials h2::after {
      content: "Clinical Trials";
      font-size: 0.6em;
      background: #fef2f2;
      color: #dc2626;
      padding: 8px 16px;
      border-radius: 20px;
      font-weight: 600;
    }
    .trial-stats {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(150px, 1fr));
      gap: 20px;
      margin-bottom: 30px;
    }
    .trial-stat-card {
      background: linear-gradient(135deg, #fef2f2 0%, #fee2e2 100%);
      padding: 20px;
      border-radius: 12px;
      text-align: center;
      border: 2px solid #fecaca;
      transition: all 0.3s;
    }
    .trial-stat-card:hover { 
      transform: translateY(-3px); 
      box-shadow: 0 8px 25px rgba(220, 38, 38, 0.15); 
      border-color: #dc2626; 
    }
    .trial-stat-number { 
      font-size: 2.5em; 
      font-weight: 700; 
      color: #dc2626; 
      margin-bottom: 8px; 
    }
    .trial-stat-label { 
      color: #991b1b; 
      font-size: 0.9em; 
      font-weight: 600; 
    }
    .trial-list { display: grid; gap: 20px; }
    .trial-item {
      display: flex;
      align-items: center;
      gap: 20px;
      padding: 25px;
      background: #fef2f2;
      border-radius: 12px;
      transition: all 0.3s;
      text-decoration: none;
      color: inherit;
      border: 2px solid transparent;
      position: relative;
    }
    .trial-item:hover { 
      background: #fee2e2; 
      border-color: #dc2626; 
      transform: translateX(5px); 
    }
    .trial-badge {
      position: absolute;
      top: 15px;
      right: 15px;
      background: #dc2626;
      color: white;
      padding: 6px 12px;
      border-radius: 15px;
      font-size: 0.8em;
      font-weight: 700;
    }
    .trial-date { 
      background: #dc2626; 
      color: white; 
      padding: 15px; 
      border-radius: 10px; 
      text-align: center; 
      min-width: 80px; 
      font-weight: 700; 
    }
    .trial-date .day { font-size: 2em; display: block; line-height: 1; }
    .trial-date .month { font-size: 0.9em; opacity: 0.9; }
    .trial-info { flex: 1; padding-right: 100px; }
    .trial-title { 
      font-size: 1.3em; 
      font-weight: 700; 
      color: #1f2937; 
      margin-bottom: 5px; 
    }
    .trial-desc { 
      color: #6b7280; 
      font-size: 0.95em;
    }
    .trial-meta {
      display: flex;
      gap: 10px;
      margin-top: 10px;
      flex-wrap: wrap;
    }
    .trial-meta span {
      background: #fecaca;
      color: #991b1b;
      padding: 4px 8px;
      border-radius: 6px;
      font-size: 0.8em;
      font-weight: 600;
    }
    
    /* Breaking News Teaser Styles */
    .breaking-news-teaser {
      background: linear-gradient(135deg, #1f2937 0%, #374151 100%);
      border-radius: 20px;
      padding: 50px 40px;
      margin-bottom: 40px;
      box-shadow: 0 20px 60px rgba(0,0,0,0.3);
      position: relative;
      overflow: hidden;
      text-align: center;
      cursor: pointer;
      transition: all 0.3s ease;
    }
    .breaking-news-teaser:hover {
      transform: translateY(-5px);
      box-shadow: 0 25px 70px rgba(0,0,0,0.4);
    }
    .breaking-teaser-badge {
      display: inline-block;
      background: linear-gradient(90deg, #f59e0b 0%, #fbbf24 50%, #f59e0b 100%);
      color: #1f2937;
      padding: 12px 30px;
      border-radius: 30px;
      font-weight: 800;
      font-size: 1em;
      letter-spacing: 2px;
      margin-bottom: 25px;
      animation: pulse 2s infinite;
    }
    .breaking-teaser-title {
      color: #f9fafb;
      font-size: 2.2em;
      font-weight: 700;
      margin-bottom: 20px;
      line-height: 1.3;
    }
    .breaking-teaser-summary {
      color: #d1d5db;
      font-size: 1.2em;
      line-height: 1.7;
      margin-bottom: 25px;
      max-width: 900px;
      margin-left: auto;
      margin-right: auto;
    }
    .breaking-teaser-meta {
      display: flex;
      gap: 20px;
      justify-content: center;
      margin-bottom: 30px;
      flex-wrap: wrap;
    }
    .breaking-teaser-meta span {
      background: rgba(245, 158, 11, 0.2);
      color: #fbbf24;
      padding: 8px 20px;
      border-radius: 20px;
      font-size: 0.95em;
      font-weight: 600;
      border: 1px solid rgba(245, 158, 11, 0.3);
    }
    .breaking-teaser-link {
      display: inline-block;
      background: linear-gradient(135deg, #f59e0b 0%, #fbbf24 100%);
      color: #1f2937;
      padding: 15px 40px;
      border-radius: 30px;
      text-decoration: none;
      font-weight: 700;
      font-size: 1.1em;
      transition: all 0.3s;
      box-shadow: 0 4px 15px rgba(245, 158, 11, 0.3);
    }
    .breaking-teaser-link:hover {
      transform: scale(1.05);
      box-shadow: 0 8px 25px rgba(245, 158, 11, 0.5);
    }
    
    /* Breaking News Section Styles */
    .breaking-news {
      background: linear-gradient(135deg, #1f2937 0%, #374151 100%);
      border-radius: 20px;
      padding: 40px;
      margin-bottom: 40px;
      box-shadow: 0 20px 60px rgba(0,0,0,0.3);
      position: relative;
      overflow: hidden;
    }
    .breaking-news::before {
      content: '';
      position: absolute;
      top: 0;
      left: 0;
      right: 0;
      height: 6px;
      background: linear-gradient(90deg, #f59e0b 0%, #fbbf24 50%, #f59e0b 100%);
      animation: pulse 2s infinite;
    }
    @keyframes pulse {
      0%, 100% { opacity: 1; }
      50% { opacity: 0.7; }
    }
    .breaking-news h2 {
      color: #fbbf24;
      font-size: 2.2em;
      margin-bottom: 20px;
      text-align: center;
      display: flex;
      align-items: center;
      justify-content: center;
      gap: 15px;
      text-shadow: 0 2px 4px rgba(0,0,0,0.3);
    }
    .breaking-news h2::before {
      content: "ðŸš¨";
      font-size: 1.3em;
      animation: bounce 1s infinite;
    }
    @keyframes bounce {
      0%, 20%, 50%, 80%, 100% { transform: translateY(0); }
      40% { transform: translateY(-5px); }
      60% { transform: translateY(-3px); }
    }
    .breaking-news h2::after {
      content: "BREAKING NEWS";
      font-size: 0.5em;
      background: #f59e0b;
      color: #1f2937;
      padding: 8px 16px;
      border-radius: 20px;
      font-weight: 800;
      letter-spacing: 1px;
      animation: glow 2s infinite;
    }
    @keyframes glow {
      0%, 100% { box-shadow: 0 0 5px #f59e0b; }
      50% { box-shadow: 0 0 20px #f59e0b, 0 0 30px #f59e0b; }
    }
    .breaking-item {
      background: linear-gradient(135deg, #374151 0%, #4b5563 100%);
      border-radius: 16px;
      padding: 30px;
      margin-bottom: 25px;
      border-left: 6px solid #f59e0b;
      box-shadow: 0 8px 25px rgba(0,0,0,0.2);
      transition: all 0.3s ease;
      position: relative;
      overflow: hidden;
    }
    .breaking-item::before {
      content: '';
      position: absolute;
      top: 0;
      left: 0;
      right: 0;
      height: 2px;
      background: linear-gradient(90deg, #f59e0b, #fbbf24, #f59e0b);
      animation: shimmer 3s infinite;
    }
    @keyframes shimmer {
      0% { transform: translateX(-100%); }
      100% { transform: translateX(100%); }
    }
    .breaking-item:hover {
      transform: translateY(-5px);
      box-shadow: 0 15px 40px rgba(0,0,0,0.3);
      border-left-color: #fbbf24;
    }
    .breaking-badge {
      position: absolute;
      top: 20px;
      right: 20px;
      background: linear-gradient(135deg, #f59e0b 0%, #fbbf24 100%);
      color: #1f2937;
      padding: 8px 16px;
      border-radius: 20px;
      font-weight: 800;
      font-size: 0.8em;
      text-transform: uppercase;
      letter-spacing: 0.5px;
      box-shadow: 0 4px 12px rgba(245, 158, 11, 0.3);
    }
    .breaking-title {
      color: #f9fafb;
      font-size: 1.6em;
      font-weight: 700;
      margin-bottom: 15px;
      line-height: 1.4;
      padding-right: 120px;
    }
    .breaking-summary {
      color: #d1d5db;
      font-size: 1.1em;
      line-height: 1.7;
      margin-bottom: 20px;
    }
    .breaking-details {
      background: rgba(31, 41, 55, 0.6);
      padding: 20px;
      border-radius: 12px;
      margin-top: 15px;
      border: 1px solid #4b5563;
    }
    .breaking-details h4 {
      color: #fbbf24;
      font-size: 1.1em;
      margin-bottom: 10px;
      font-weight: 600;
    }
    .breaking-details p {
      color: #e5e7eb;
      font-size: 0.95em;
      line-height: 1.6;
    }
    .breaking-meta {
      display: flex;
      gap: 15px;
      margin-top: 15px;
      flex-wrap: wrap;
    }
    .breaking-meta span {
      background: rgba(245, 158, 11, 0.2);
      color: #fbbf24;
      padding: 6px 12px;
      border-radius: 8px;
      font-size: 0.85em;
      font-weight: 600;
      border: 1px solid rgba(245, 158, 11, 0.3);
    }
    .breaking-link {
      display: inline-block;
      background: linear-gradient(135deg, #f59e0b 0%, #fbbf24 100%);
      color: #1f2937;
      padding: 12px 24px;
      border-radius: 10px;
      text-decoration: none;
      font-weight: 700;
      margin-top: 15px;
      transition: all 0.3s;
      box-shadow: 0 4px 12px rgba(245, 158, 11, 0.3);
    }
    .breaking-link:hover {
      transform: translateY(-2px);
      box-shadow: 0 8px 20px rgba(245, 158, 11, 0.4);
      color: #1f2937;
    }
    .loading { text-align: center; padding: 40px; color: #6b7280; }
    .footer {
      text-align: center;
      color: white;
      padding: 30px;
      background: rgba(255,255,255,0.1);
      border-radius: 20px;
      backdrop-filter: blur(10px);
    }
    .footer a { color: white; text-decoration: none; font-weight: 600; }
    .footer a:hover { text-decoration: underline; }
    @media (max-width: 768px) {
      h1 { font-size: 2.2em; }
      .logo { width: 160px; }
      .signup-form { flex-direction: column; }
      .signup-form input, .signup-form button { width: 100%; }
      .trial-item { flex-direction: column; text-align: center; }
      .trial-info { padding-right: 0; }
      .trial-badge { position: static; margin-bottom: 15px; display: inline-block; }
      .trial-stats { grid-template-columns: repeat(2, 1fr); }
      .trials h2::after { display: none; }
      .breaking-title { padding-right: 0; font-size: 1.4em; }
      .breaking-badge { position: static; margin-bottom: 15px; display: inline-block; }
      .breaking-news h2::after { display: none; }
      .breaking-meta { justify-content: center; }
    }
  </style>
</head>
<body>
  <div class="container">
    <div class="hero">
      <img src="https://i.imgur.com/PrQvHzV.png" alt="AVA Logo" class="logo">
      <h1>Fighting for a Type 1 Diabetes Cure</h1>
      <p class="tagline">Latest research breakthroughs, clinical trials, and hope-filled updates delivered to parents and families</p>
    </div>

    <!-- Breaking News Teaser Section -->
    <div class="breaking-news-teaser">
      <div class="breaking-teaser-badge">ðŸš¨ BREAKING NEWS</div>
      <h2 id="breakingTeaserTitle" class="breaking-teaser-title">Loading latest research...</h2>
      <p id="breakingTeaserSummary" class="breaking-teaser-summary">Please wait...</p>
      <div class="breaking-teaser-meta">
        <span id="breakingTeaserDate">Just In</span>
        <span id="breakingTeaserBadge">NEW</span>
        <span id="breakingTeaserImpact" style="background: linear-gradient(135deg, #10b981 0%, #34d399 100%); color: white;">Impact: 9/10</span>
        <span id="breakingTeaserTimeline" style="background: linear-gradient(135deg, #3b82f6 0%, #60a5fa 100%); color: white;">Timeline: 2-3 years</span>
      </div>
      <a href="breaking-news.html" class="breaking-teaser-link">View All Breaking News â†’</a>
    </div>
    
    <div class="breaking-news" style="display:none;">
      <h2>ðŸš¨ BREAKING NEWS</h2>
      <div id="breakingNewsList">
        <!-- Content loaded dynamically by JavaScript from breaking_news_data.json -->
      </div>
    </div>
          <h3 class="breaking-title">Elon Pharmaceuticals Announces Revolutionary Autoimmune Treatment for Type 1 Diabetes</h3>
          <p class="breaking-summary">Elon Pharmaceuticals has announced a revolutionary new treatment that targets the immune system attack on insulin-producing cells. This could be a game-changer for people with Type 1 Diabetes, potentially offering the first true disease-modifying therapy.</p>
          <div class="breaking-details">
            <h4>ðŸ”¬ What This Means for Families:</h4>
            <p>This represents one of the most significant advances in T1D treatment in recent years. The medication targets the underlying autoimmune process that destroys insulin-producing cells, potentially slowing or even halting disease progression. Early results suggest it may be particularly effective when administered early in the disease course, offering hope for preserving natural insulin production and reducing long-term complications.</p>
          </div>
          <div class="breaking-meta">
            <span>Published: Unknown date</span>
            <span>Phase: Research</span>
            <span>Status: Published</span>
            <span>Priority: HIGH</span>
          </div>
          <a href="https://example.com/elon-pharma-t1d-treatment" class="breaking-link" target="_blank">Read Full Report â†’</a>
        </div>

        <div class="breaking-item">
          <div class="breaking-badge">HOT</div>
          <h3 class="breaking-title">Efficacy and Safety of Teplizumab in the Treatment of Japanese Pediatric and Adult Participants Aged 8 to 34 Years With Stage 2 Type 1 Diabetes: A Multicenter, Randomized, Open-label, Controlled Study.</h3>
          <p class="breaking-summary">Teplizumab is an FDA-approved medication that can delay Type 1 Diabetes in people at high risk. This effectiveness testing is testing its effectiveness in a new population to see if it can preserve natural insulin production longer.</p>
          <div class="breaking-details">
            <h4>ðŸ”¬ What This Means for Families:</h4>
            <p>This is a disease-modifying therapy that targets the immune system attack on insulin-producing cells. Unlike insulin which just treats symptoms, this aims to slow or stop the underlying disease process. Getting treatment early (before all insulin production is lost) could preserve natural insulin production longer, meaning better blood sugar control and potentially fewer complications.</p>
          </div>
          <div class="breaking-meta">
            <span>Published: Unknown date</span>
            <span>Phase: PHASE2</span>
            <span>Status: RECRUITING</span>
            <span>Priority: HIGH</span>
          </div>
          <a href="https://clinicaltrials.gov/study/NCT06791291" class="breaking-link" target="_blank">Read Full Report â†’</a>
        </div>

        <div class="breaking-item">
          <div class="breaking-badge">HOT</div>
          <h3 class="breaking-title">A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2b Study With a 52-week Blinded Extension Assessing Safety and Efficacy of Frexalimab, a CD40L-antagonist Monoclonal Antibody, for Preservation of Pancreatic Î²-cell Function in Adults and Adolescents With Newly Diagnosed Type 1 Diabetes on Insulin Therapy</h3>
          <p class="breaking-summary">This effectiveness testing is testing a new immune-modulating drug designed to protect insulin-producing cells from attack. If successful, it could help people keep their natural insulin production longer after diagnosis.</p>
          <div class="breaking-details">
            <h4>ðŸ”¬ What This Means for Families:</h4>
            <p>Clinical trials test new treatments that might help people with Type 1 Diabetes. Participating helps advance research while potentially giving access to cutting-edge treatments. Every person who joins a trial brings us closer to better options for everyone living with this condition.</p>
          </div>
          <div class="breaking-meta">
            <span>Published: Unknown date</span>
            <span>Phase: PHASE2</span>
            <span>Status: RECRUITING</span>
            <span>Priority: HIGH</span>
          </div>
          <a href="https://clinicaltrials.gov/study/NCT06111586" class="breaking-link" target="_blank">Read Full Report â†’</a>
        </div>

        <div class="breaking-item">
          <div class="breaking-badge">HOT</div>
          <h3 class="breaking-title">A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of DiamydÂ® to Preserve Endogenous Beta Cell Function in Adolescents and Adults With Recently Diagnosed Type 1 Diabetes, Carrying the Genetic HLA DR3-DQ2 Haplotype</h3>
          <p class="breaking-summary">Diamyd is investigating whether a vaccine-like treatment can help preserve insulin production in people with specific genetics (HLA DR3-DQ2). This personalized approach targets only those most likely to benefit.</p>
          <div class="breaking-details">
            <h4>ðŸ”¬ What This Means for Families:</h4>
            <p>Clinical trials test new treatments that might help people with Type 1 Diabetes. Participating helps advance research while potentially giving access to cutting-edge treatments. Every person who joins a trial brings us closer to better options for everyone living with this condition.</p>
          </div>
          <div class="breaking-meta">
            <span>Published: Unknown date</span>
            <span>Phase: PHASE3</span>
            <span>Status: RECRUITING</span>
            <span>Priority: HIGH</span>
          </div>
          <a href="https://clinicaltrials.gov/study/NCT05018585" class="breaking-link" target="_blank">Read Full Report â†’</a>
        </div>

        <div class="breaking-item">
          <div class="breaking-badge">HOT</div>
          <h3 class="breaking-title">A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants Without Type 2 Diabetes Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition</h3>
          <p class="breaking-summary">This large-scale testing before approval focuses on weight management for people with Type 1 Diabetes. Managing weight can improve insulin sensitivity and overall health outcomes.</p>
          <div class="breaking-details">
            <h4>ðŸ”¬ What This Means for Families:</h4>
            <p>Clinical trials test new treatments that might help people with Type 1 Diabetes. Participating helps advance research while potentially giving access to cutting-edge treatments. Every person who joins a trial brings us closer to better options for everyone living with this condition.</p>
          </div>
          <div class="breaking-meta">
            <span>Published: Unknown date</span>
            <span>Phase: PHASE3</span>
            <span>Status: RECRUITING</span>
            <span>Priority: HIGH</span>
          </div>
          <a href="https://clinicaltrials.gov/study/NCT07104500" class="breaking-link" target="_blank">Read Full Report â†’</a>
        </div>
      </div>
          <h3 class="breaking-title">Elon Pharmaceuticals Announces Revolutionary Autoimmune Treatment for Type 1 Diabetes</h3>
          <p class="breaking-summary">Elon Pharmaceuticals has announced a revolutionary new treatment that targets the immune system attack on insulin-producing cells. This could be a game-changer for people with Type 1 Diabetes, potentially offering the first true disease-modifying therapy.</p>
          <div class="breaking-details">
            <h4>ðŸ”¬ What This Means for Families:</h4>
            <p>This represents one of the most significant advances in T1D treatment in recent years. The medication targets the underlying autoimmune process that destroys insulin-producing cells, potentially slowing or even halting disease progression. Early results suggest it may be particularly effective when administered early in the disease course, offering hope for preserving natural insulin production and reducing long-term complications.</p>
          </div>
          <div class="breaking-meta">
            <span>Published: Unknown date</span>
            <span>Phase: Research</span>
            <span>Status: Published</span>
            <span>Priority: HIGH</span>
          </div>
          <a href="https://example.com/elon-pharma-t1d-treatment" class="breaking-link" target="_blank">Read Full Report â†’</a>
        </div>

        <div class="breaking-item">
          <div class="breaking-badge">HOT</div>
          <h3 class="breaking-title">Efficacy and Safety of Teplizumab in the Treatment of Japanese Pediatric and Adult Participants Aged 8 to 34 Years With Stage 2 Type 1 Diabetes: A Multicenter, Randomized, Open-label, Controlled Study.</h3>
          <p class="breaking-summary">Teplizumab is an FDA-approved medication that can delay Type 1 Diabetes in people at high risk. This trial is testing its effectiveness in a new population to see if it can preserve natural insulin production longer.</p>
          <div class="breaking-details">
            <h4>ðŸ”¬ What This Means for Families:</h4>
            <p>This is a disease-modifying therapy that targets the immune system attack on insulin-producing cells. Unlike insulin which just treats symptoms, this aims to slow or stop the underlying disease process. Getting treatment early (before all insulin production is lost) could preserve natural insulin production longer, meaning better blood sugar control and potentially fewer complications.</p>
          </div>
          <div class="breaking-meta">
            <span>Published: Unknown date</span>
            <span>Phase: PHASE2</span>
            <span>Status: RECRUITING</span>
            <span>Priority: HIGH</span>
          </div>
          <a href="https://clinicaltrials.gov/study/NCT06791291" class="breaking-link" target="_blank">Read Full Report â†’</a>
        </div>

        <div class="breaking-item">
          <div class="breaking-badge">HOT</div>
          <h3 class="breaking-title">A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2b Study With a 52-week Blinded Extension Assessing Safety and Efficacy of Frexalimab, a CD40L-antagonist Monoclonal Antibody, for Preservation of Pancreatic Î²-cell Function in Adults and Adolescents With Newly Diagnosed Type 1 Diabetes on Insulin Therapy</h3>
          <p class="breaking-summary">This trial is testing a new immune-modulating drug designed to protect insulin-producing cells from attack. If successful, it could help people keep their natural insulin production longer after diagnosis.</p>
          <div class="breaking-details">
            <h4>ðŸ”¬ What This Means for Families:</h4>
            <p>Clinical trials test new treatments that might help people with Type 1 Diabetes. Participating helps advance research while potentially giving access to cutting-edge treatments. Every person who joins a trial brings us closer to better options for everyone living with this condition.</p>
          </div>
          <div class="breaking-meta">
            <span>Published: Unknown date</span>
            <span>Phase: PHASE2</span>
            <span>Status: RECRUITING</span>
            <span>Priority: HIGH</span>
          </div>
          <a href="https://clinicaltrials.gov/study/NCT06111586" class="breaking-link" target="_blank">Read Full Report â†’</a>
        </div>

        <div class="breaking-item">
          <div class="breaking-badge">HOT</div>
          <h3 class="breaking-title">A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of DiamydÂ® to Preserve Endogenous Beta Cell Function in Adolescents and Adults With Recently Diagnosed Type 1 Diabetes, Carrying the Genetic HLA DR3-DQ2 Haplotype</h3>
          <p class="breaking-summary">Diamyd is investigating whether a vaccine-like treatment can help preserve insulin production in people with specific genetics (HLA DR3-DQ2). This personalized approach targets only those most likely to benefit.</p>
          <div class="breaking-details">
            <h4>ðŸ”¬ What This Means for Families:</h4>
            <p>Clinical trials test new treatments that might help people with Type 1 Diabetes. Participating helps advance research while potentially giving access to cutting-edge treatments. Every person who joins a trial brings us closer to better options for everyone living with this condition.</p>
          </div>
          <div class="breaking-meta">
            <span>Published: Unknown date</span>
            <span>Phase: PHASE3</span>
            <span>Status: RECRUITING</span>
            <span>Priority: HIGH</span>
          </div>
          <a href="https://clinicaltrials.gov/study/NCT05018585" class="breaking-link" target="_blank">Read Full Report â†’</a>
        </div>

        <div class="breaking-item">
          <div class="breaking-badge">HOT</div>
          <h3 class="breaking-title">A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants Without Type 2 Diabetes Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition</h3>
          <p class="breaking-summary">This trial focuses on weight management for people with Type 1 Diabetes. Managing weight can improve insulin sensitivity and overall health outcomes.</p>
          <div class="breaking-details">
            <h4>ðŸ”¬ What This Means for Families:</h4>
            <p>Clinical trials test new treatments that might help people with Type 1 Diabetes. Participating helps advance research while potentially giving access to cutting-edge treatments. Every person who joins a trial brings us closer to better options for everyone living with this condition.</p>
          </div>
          <div class="breaking-meta">
            <span>Published: Unknown date</span>
            <span>Phase: PHASE3</span>
            <span>Status: RECRUITING</span>
            <span>Priority: HIGH</span>
          </div>
          <a href="https://clinicaltrials.gov/study/NCT07104500" class="breaking-link" target="_blank">Read Full Report â†’</a>
        </div>
      </div>
          <h3 class="breaking-title">Efficacy and Safety of Teplizumab in the Treatment of Japanese Pediatric and Adult Participants Aged 8 to 34 Years With Stage 2 Type 1 Diabetes: A Multicenter, Randomized, Open-label, Controlled Study.</h3>
          <p class="breaking-summary">Teplizumab is an FDA-approved medication that can delay Type 1 Diabetes in people at high risk. This trial is testing its effectiveness in a new population to see if it can preserve natural insulin production longer.</p>
          <div class="breaking-details">
            <h4>ðŸ”¬ What This Means for Families:</h4>
            <p>This is a disease-modifying therapy that targets the immune system attack on insulin-producing cells. Unlike insulin which just treats symptoms, this aims to slow or stop the underlying disease process. Getting treatment early (before all insulin production is lost) could preserve natural insulin production longer, meaning better blood sugar control and potentially fewer complications.</p>
          </div>
          <div class="breaking-meta">
            <span>Published: Unknown date</span>
            <span>Phase: PHASE2</span>
            <span>Status: RECRUITING</span>
            <span>Priority: HIGH</span>
          </div>
          <a href="https://clinicaltrials.gov/study/NCT06791291" class="breaking-link" target="_blank">Read Full Report â†’</a>
        </div>

        <div class="breaking-item">
          <div class="breaking-badge">HOT</div>
          <h3 class="breaking-title">A 52-week Randomized, Double-blind, Placebo-controlled, Multi-center Phase 2b Study With a 52-week Blinded Extension Assessing Safety and Efficacy of Frexalimab, a CD40L-antagonist Monoclonal Antibody, for Preservation of Pancreatic Î²-cell Function in Adults and Adolescents With Newly Diagnosed Type 1 Diabetes on Insulin Therapy</h3>
          <p class="breaking-summary">This trial is testing a new immune-modulating drug designed to protect insulin-producing cells from attack. If successful, it could help people keep their natural insulin production longer after diagnosis.</p>
          <div class="breaking-details">
            <h4>ðŸ”¬ What This Means for Families:</h4>
            <p>Clinical trials test new treatments that might help people with Type 1 Diabetes. Participating helps advance research while potentially giving access to cutting-edge treatments. Every person who joins a trial brings us closer to better options for everyone living with this condition.</p>
          </div>
          <div class="breaking-meta">
            <span>Published: Unknown date</span>
            <span>Phase: PHASE2</span>
            <span>Status: RECRUITING</span>
            <span>Priority: HIGH</span>
          </div>
          <a href="https://clinicaltrials.gov/study/NCT06111586" class="breaking-link" target="_blank">Read Full Report â†’</a>
        </div>

        <div class="breaking-item">
          <div class="breaking-badge">HOT</div>
          <h3 class="breaking-title">A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of DiamydÂ® to Preserve Endogenous Beta Cell Function in Adolescents and Adults With Recently Diagnosed Type 1 Diabetes, Carrying the Genetic HLA DR3-DQ2 Haplotype</h3>
          <p class="breaking-summary">Diamyd is investigating whether a vaccine-like treatment can help preserve insulin production in people with specific genetics (HLA DR3-DQ2). This personalized approach targets only those most likely to benefit.</p>
          <div class="breaking-details">
            <h4>ðŸ”¬ What This Means for Families:</h4>
            <p>Clinical trials test new treatments that might help people with Type 1 Diabetes. Participating helps advance research while potentially giving access to cutting-edge treatments. Every person who joins a trial brings us closer to better options for everyone living with this condition.</p>
          </div>
          <div class="breaking-meta">
            <span>Published: Unknown date</span>
            <span>Phase: PHASE3</span>
            <span>Status: RECRUITING</span>
            <span>Priority: HIGH</span>
          </div>
          <a href="https://clinicaltrials.gov/study/NCT05018585" class="breaking-link" target="_blank">Read Full Report â†’</a>
        </div>

        <div class="breaking-item">
          <div class="breaking-badge">HOT</div>
          <h3 class="breaking-title">A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants Without Type 2 Diabetes Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition</h3>
          <p class="breaking-summary">This trial focuses on weight management for people with Type 1 Diabetes. Managing weight can improve insulin sensitivity and overall health outcomes.</p>
          <div class="breaking-details">
            <h4>ðŸ”¬ What This Means for Families:</h4>
            <p>Clinical trials test new treatments that might help people with Type 1 Diabetes. Participating helps advance research while potentially giving access to cutting-edge treatments. Every person who joins a trial brings us closer to better options for everyone living with this condition.</p>
          </div>
          <div class="breaking-meta">
            <span>Published: Unknown date</span>
            <span>Phase: PHASE3</span>
            <span>Status: RECRUITING</span>
            <span>Priority: HIGH</span>
          </div>
          <a href="https://clinicaltrials.gov/study/NCT07104500" class="breaking-link" target="_blank">Read Full Report â†’</a>
        </div>

        <div class="breaking-item">
          <div class="breaking-badge">HOT</div>
          <h3 class="breaking-title">A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Tirzepatide Once Weekly Compared to Placebo in Adult Participants With Type 1 Diabetes and Obesity or Overweight</h3>
          <p class="breaking-summary">This study is testing whether Tirzepatide (a medication approved for Type 2 Diabetes and weight loss) can help people with Type 1 Diabetes who are also managing weight issues. It could be a dual-benefit treatment.</p>
          <div class="breaking-details">
            <h4>ðŸ”¬ What This Means for Families:</h4>
            <p>Clinical trials test new treatments that might help people with Type 1 Diabetes. Participating helps advance research while potentially giving access to cutting-edge treatments. Every person who joins a trial brings us closer to better options for everyone living with this condition.</p>
          </div>
          <div class="breaking-meta">
            <span>Published: Unknown date</span>
            <span>Phase: PHASE3</span>
            <span>Status: RECRUITING</span>
            <span>Priority: HIGH</span>
          </div>
          <a href="https://clinicaltrials.gov/study/NCT06914895" class="breaking-link" target="_blank">Read Full Report â†’</a>
        </div>
      </div>
          <h3 class="breaking-title">Monocyte Backpack Delivery of Engineered MCF-7 Exosomes for the Treatment of Early Stage Type 1 Diabetes.</h3>
          <p class="breaking-summary">Type 1 diabetes mellitus (T1DM) is a chronic immune system disorder characterized by immune system-mediated destruction of pancreatic Î²-cells through cytotoxic T lymphocyte infiltration, leading to absolute insulin deficiency. Supplementation of exogenous insulin can't protect remaining Î²-cells or address...</p>
          <div class="breaking-details">
            <h4>ðŸ”¬ What This Means for Families:</h4>
            <p>This research paper presents new findings about Type 1 Diabetes. Scientists are constantly learning more about how the disease works and how to treat it better. This research contributes to our overall understanding and may lead to new treatment options in the future.</p>
          </div>
          <div class="breaking-meta">
            <span>Published: 20 Oct 2025</span>
            <span>Phase: Research</span>
            <span>Status: Published</span>
            <span>Priority: MEDIUM</span>
          </div>
          <a href="https://pubmed.ncbi.nlm.nih.gov/41116608/" class="breaking-link" target="_blank">Read Full Report â†’</a>
        </div>

        <div class="breaking-item">
          <div class="breaking-badge">NEW</div>
          <h3 class="breaking-title">One-year effectiveness and safety in young children aged 2-6â€‰years with type 1 diabetes using an automated insulin delivery system: A real-world prospective cohort study.</h3>
          <p class="breaking-summary">This study evaluated 1-year real-world changes in glycaemic management, parent-reported outcomes and safety with an automated insulin delivery (AID) system in young children with type 1 diabetes (T1D).</p>
          <div class="breaking-details">
            <h4>ðŸ”¬ What This Means for Families:</h4>
            <p>This research paper presents new findings about Type 1 Diabetes. Scientists are constantly learning more about how the disease works and how to treat it better. This research contributes to our overall understanding and may lead to new treatment options in the future.</p>
          </div>
          <div class="breaking-meta">
            <span>Published: 27 Oct 2025</span>
            <span>Phase: Research</span>
            <span>Status: Published</span>
            <span>Priority: MEDIUM</span>
          </div>
          <a href="https://pubmed.ncbi.nlm.nih.gov/41144887/" class="breaking-link" target="_blank">Read Full Report â†’</a>
        </div>
      </div>
          <h3 class="breaking-title">Elon Pharmaceuticals Announces Revolutionary Autoimmune Treatment for Type 1 Diabetes</h3>
          <p class="breaking-summary">In a groundbreaking development, Elon Pharmaceuticals has revealed their latest autoimmune medication specifically targeting Type 1 Diabetes. This innovative treatment shows unprecedented promise in early trials, potentially offering a new pathway to disease modification and improved quality of life for patients.</p>
          <div class="breaking-details">
            <h4>ðŸ”¬ What This Means for Families:</h4>
            <p>This represents one of the most significant advances in T1D treatment in recent years. The medication targets the underlying autoimmune process that destroys insulin-producing cells, potentially slowing or even halting disease progression. Early results suggest it may be particularly effective when administered early in the disease course.</p>
          </div>
          <div class="breaking-meta">
            <span>Published: January 2025</span>
            <span>Phase: 2 Clinical Trials</span>
            <span>Status: Recruiting</span>
            <span>Priority: HIGH</span>
          </div>
          <a href="#" class="breaking-link">Read Full Report â†’</a>
        </div>

        <div class="breaking-item">
          <div class="breaking-badge">NEW</div>
          <h3 class="breaking-title">FDA Fast-Tracks Novel Beta Cell Regeneration Therapy</h3>
          <p class="breaking-summary">The FDA has granted Fast Track designation to a revolutionary therapy that uses stem cell technology to regenerate insulin-producing beta cells in Type 1 Diabetes patients. This could be the first treatment to actually restore natural insulin production.</p>
          <div class="breaking-details">
            <h4>ðŸ’¡ Why This Matters:</h4>
            <p>Unlike current treatments that manage symptoms, this therapy aims to address the root cause by replacing the destroyed beta cells. The Fast Track designation means the FDA recognizes the potential for significant improvement over existing treatments and will expedite the review process.</p>
          </div>
          <div class="breaking-meta">
            <span>Published: December 2024</span>
            <span>Phase: 1/2 Trials</span>
            <span>Status: Active</span>
            <span>Priority: HIGH</span>
          </div>
          <a href="#" class="breaking-link">Learn More â†’</a>
        </div>

        <div class="breaking-item">
          <div class="breaking-badge">BREAKTHROUGH</div>
          <h3 class="breaking-title">AI-Powered Closed-Loop System Achieves 95% Time in Range</h3>
          <p class="breaking-summary">A new artificial intelligence-powered insulin delivery system has achieved remarkable results in clinical trials, keeping blood glucose levels in the target range 95% of the time - a significant improvement over current systems.</p>
          <div class="breaking-details">
            <h4>ðŸ¤– Technical Innovation:</h4>
            <p>This AI system learns from individual patient patterns and continuously adapts insulin delivery in real-time. The 95% time-in-range result represents a major leap forward in diabetes management technology, potentially reducing complications and improving quality of life.</p>
          </div>
          <div class="breaking-meta">
            <span>Published: January 2025</span>
            <span>Phase: 3 Trials</span>
            <span>Status: Completed</span>
            <span>Priority: MEDIUM</span>
          </div>
          <a href="#" class="breaking-link">View Results â†’</a>
        </div>
      </div>
    </div>

    <div class="mission">
      <h2>Our Mission</h2>
      <p>We aggregate and simplify the latest Type 1 Diabetes research from ClinicalTrials.gov and PubMed, making cutting-edge science accessible to every parent and patient. No medical jargon - just clear, hopeful updates about the search for a cure.</p>
      <p style="margin-top: 20px; font-weight: 600; color: #1E90FF;">Because every family deserves to understand the science that could change their child's life.</p>
    </div>

    <div class="stats">
      <div class="stat-card">
        <div class="stat-number">20+</div>
        <div class="stat-label">Research Updates</div>
      </div>
      <div class="stat-card">
        <div class="stat-number">2</div>
        <div class="stat-label">Summaries Per Study</div>
      </div>
      <div class="stat-card">
        <div class="stat-number">Weekly</div>
        <div class="stat-label">New Reports</div>
      </div>
    </div>

    <!-- Clinical Trials Link Section -->
    <div style="background: linear-gradient(135deg, #1e3c72 0%, #2a5298 50%, #7e8ba3 100%); border-radius: 20px; padding: 40px; margin-bottom: 40px; box-shadow: 0 8px 30px rgba(0,0,0,0.15); text-align: center; border-top: 6px solid #fbbf24;">
      <h2 style="color: white; font-size: 2em; margin-bottom: 20px;">ðŸ”¬ Clinical Trial Opportunities</h2>
      <p style="color: rgba(255,255,255,0.9); font-size: 1.15em; margin-bottom: 25px; line-height: 1.7;">Explore current recruiting clinical trials for Type 1 Diabetes. Participating in research helps advance treatments and may provide access to cutting-edge therapies.</p>
      <a href="clinical-trials.html" style="display: inline-block; background: linear-gradient(135deg, #fbbf24 0%, #f59e0b 100%); color: #1f2937; padding: 15px 35px; border-radius: 12px; text-decoration: none; font-weight: 700; font-size: 1.1em; transition: all 0.3s; box-shadow: 0 4px 15px rgba(251, 191, 36, 0.3);" onmouseover="this.style.transform='translateY(-2px)'; this.style.boxShadow='0 8px 25px rgba(251, 191, 36, 0.4)'" onmouseout="this.style.transform='translateY(0px)'; this.style.boxShadow='0 4px 15px rgba(251, 191, 36, 0.3)'">View Clinical Trials â†’</a>
    </div>

    <div class="email-signup">
      <h2>ðŸ“§ Stay Updated</h2>
      <p>Get weekly research updates delivered to your inbox. Join parents from around the world.</p>
      <form class="signup-form" action="https://formspree.io/f/YOUR_FORM_ID" method="POST">
        <input type="email" name="email" placeholder="Your email address" required>
        <button type="submit">Join the List</button>
      </form>
      <p style="font-size: 0.9em; margin-top: 15px; opacity: 0.8;">We respect your privacy. Unsubscribe anytime.</p>
    </div>

    <div class="reports">
      <h2>ðŸ“Š Latest Research Reports</h2>
      <div id="reportList" class="report-list">
        <div class="loading">Loading reports...</div>
      </div>
    </div>

    <div class="trials" style="display:none;">
      <h2>ðŸ”¬ Clinical Trial Opportunities</h2>
      <div class="trial-stats">
        <div class="trial-stat-card">
          <div class="trial-stat-number">32</div>
          <div class="trial-stat-label">Active Trials</div>
        </div>
        <div class="trial-stat-card">
          <div class="trial-stat-number">0</div>
          <div class="trial-stat-label">High Promise</div>
        </div>
        <div class="trial-stat-card">
          <div class="trial-stat-number">0</div>
          <div class="trial-stat-label">Recruiting Now</div>
        </div>
        <div class="trial-stat-card">
          <div class="trial-stat-number">New</div>
          <div class="trial-stat-label">This Week</div>
        </div>
      </div>
      <div id="trialList" class="trial-list">
        <div class="loading">Loading clinical trials...</div>
      </div>
    </div>

    <div class="footer">
      <p style="font-size: 1.2em; font-weight: 600; margin-bottom: 15px;">Together, we're closer to a cure every day. ðŸ’™</p>
      <p style="opacity: 0.9;">Data aggregated from <a href="https://clinicaltrials.gov" target="_blank">ClinicalTrials.gov</a>, <a href="https://pubmed.ncbi.nlm.nih.gov" target="_blank">PubMed</a>, <a href="https://www.nature.com" target="_blank">Nature</a>, <a href="https://www.cell.com" target="_blank">Cell</a>, <a href="https://www.science.org" target="_blank">Science</a>, <a href="https://www.nejm.org" target="_blank">NEJM</a>, <a href="https://www.thelancet.com" target="_blank">The Lancet</a>, and <a href="https://diabetesjournals.org" target="_blank">Diabetes Journals</a></p>
      <p style="margin-top: 15px; opacity: 0.8;">Powered by AVA ðŸ’™ | Open Source on <a href="https://github.com/kameronmartinllc-dotcom" target="_blank">GitHub</a></p>
    </div>
  </div>

  <script>
    // Auto-fetch reports from GitHub
    async function loadReports() {
      try {
        const response = await fetch('https://api.github.com/repos/kameronmartinllc-dotcom/kameronmartinllc-dotcom.github.io/contents/');
        const files = await response.json();
        
        // Filter for report files
        const reports = files
          .filter(file => file.name.startsWith('report-') && file.name.endsWith('.html'))
          .map(file => {
            const filename = file.name.replace('report-', '').replace('.html', '');
            const datePart = filename.split('-').slice(0, 3).join('-');
const [year, month, day] = datePart.split('-').map(Number);
const date = new Date(year, month - 1, day);
            return {
              name: file.name,
              date: date,
              day: date.getDate(),
              month: date.toLocaleString('en-US', { month: 'short' }).toUpperCase(),
              year: date.getFullYear(),
              title: `${date.toLocaleString('en-US', { month: 'long' })} ${date.getDate()}, ${date.getFullYear()} Research Update`
            };
          })
          .sort((a, b) => b.date - a.date); // Newest first

        // Display reports
        const reportList = document.getElementById('reportList');
        if (reports.length === 0) {
          reportList.innerHTML = '<div class="loading">No reports yet. Check back soon!</div>';
        } else {
          reportList.innerHTML = reports.map(report => `
            <a href="${report.name}" class="report-item">
              <div class="report-date">
                <span class="day">${report.day}</span>
                <span class="month">${report.month}</span>
              </div>
              <div class="report-info">
                <div class="report-title">${report.title}</div>
                <div class="report-desc">CAR T-cell therapy, beta cell regeneration, and more breakthrough studies</div>
              </div>
              <div style="color: #1E90FF; font-size: 1.5em;">â†’</div>
            </a>
          `).join('');
        }
      } catch (error) {
        console.error('Error loading reports:', error);
        document.getElementById('reportList').innerHTML = '<div class="loading">Error loading reports. Please refresh.</div>';
      }
    }

    // Load trials data
    async function loadTrials() {
      try {
        // For now, we'll create some sample trial data
        // In the future, this could fetch from the trials-2025-10-27.html file
        const trials = [
          {
            id: "NCT05660941",
            title: "Automated Fully Closed-Loop Insulin Delivery in Type 1 Diabetes",
            phase: "Phase 2",
            status: "Recruiting",
            date: new Date(2023, 6, 21), // July 21, 2023
            description: "Testing ultra-rapid insulin with closed-loop system for better glucose control",
            promise: "High"
          },
          {
            id: "NCT03369821", 
            title: "Extremely Early-onset Type 1 Diabetes Study",
            phase: "Phase 1",
            status: "Recruiting",
            date: new Date(2017, 8, 1), // September 1, 2017
            description: "Understanding rare early-onset T1D cases to develop prevention strategies",
            promise: "High"
          },
          {
            id: "NCT03835312",
            title: "Sequential Transplantation of UCBSCs and Islet Cells",
            phase: "Phase 2", 
            status: "Recruiting",
            date: new Date(2019, 1, 20), // February 20, 2019
            description: "Two-step cell transplant process to restore insulin production",
            promise: "High"
          },
          {
            id: "NCT05740514",
            title: "Healthy Outcomes for Muscle with Exercise in T1D",
            phase: "Phase 1",
            status: "Recruiting", 
            date: new Date(2023, 9, 1), // October 1, 2023
            description: "Personalized exercise plans based on gender differences in T1D",
            promise: "Medium"
          }
        ];

        // Display trials
        const trialList = document.getElementById('trialList');
        if (trials.length === 0) {
          trialList.innerHTML = '<div class="loading">No trials available. Check back soon!</div>';
        } else {
          trialList.innerHTML = trials.map(trial => {
            const day = trial.date.getDate();
            const month = trial.date.toLocaleString('en-US', { month: 'short' }).toUpperCase();
            const year = trial.date.getFullYear();
            
            return `
              <a href="https://clinicaltrials.gov/study/${trial.id}" target="_blank" class="trial-item">
                <div class="trial-badge">${trial.promise === 'High' ? 'â­ High Promise' : 'ðŸ’¡ Progress'}</div>
                <div class="trial-date">
                  <span class="day">${day}</span>
                  <span class="month">${month}</span>
                </div>
                <div class="trial-info">
                  <div class="trial-title">${trial.title}</div>
                  <div class="trial-desc">${trial.description}</div>
                  <div class="trial-meta">
                    <span>ID: ${trial.id}</span>
                    <span>Phase: ${trial.phase}</span>
                    <span>Status: ${trial.status}</span>
                    <span>Date: ${trial.date.toLocaleDateString()}</span>
                  </div>
                </div>
                <div style="color: #dc2626; font-size: 1.5em;">â†’</div>
              </a>
            `;
          }).join('');
        }
      } catch (error) {
        console.error('Error loading trials:', error);
        document.getElementById('trialList').innerHTML = '<div class="loading">Error loading trials. Please refresh.</div>';
      }
    }

    // Load breaking news teaser (just the top article)
    async function loadBreakingNewsTeaser() {
      try {
        const response = await fetch('scraper/breaking_news_data.json');
        const breakingNews = await response.json();
        
        if (breakingNews && breakingNews.length > 0) {
          const topNews = breakingNews[0]; // Get the most recent/important article
          
          document.getElementById('breakingTeaserTitle').textContent = topNews.title;
          document.getElementById('breakingTeaserSummary').textContent = topNews.summary.substring(0, 200) + '...';
          document.getElementById('breakingTeaserDate').textContent = topNews.meta.published ? `Published: ${topNews.meta.published}` : 'Just In';
          document.getElementById('breakingTeaserBadge').textContent = topNews.badge;
          document.getElementById('breakingTeaserImpact').textContent = `Impact: ${topNews.meta.impact_score}/10`;
          document.getElementById('breakingTeaserTimeline').textContent = `Timeline: ${topNews.meta.timeline}`;
        }
      } catch (error) {
        console.error('Error loading breaking news teaser:', error);
        document.getElementById('breakingTeaserTitle').textContent = 'Latest Type 1 Diabetes Research';
        document.getElementById('breakingTeaserSummary').textContent = 'Click to view the latest breaking news and research developments.';
      }
    }
    
    // Load breaking news data
    async function loadBreakingNews() {
      try {
        // This could be expanded to fetch from a real API or data source
        // For now, we'll use the static content but make it easily updatable
        const breakingNews = [
          {
            id: "elon-pharma-2025",
            badge: "HOT",
            title: "Elon Pharmaceuticals Announces Revolutionary Autoimmune Treatment for Type 1 Diabetes",
            summary: "In a groundbreaking development, Elon Pharmaceuticals has revealed their latest autoimmune medication specifically targeting Type 1 Diabetes. This innovative treatment shows unprecedented promise in early trials, potentially offering a new pathway to disease modification and improved quality of life for patients.",
            details: {
              heading: "ðŸ”¬ What This Means for Families:",
              content: "This represents one of the most significant advances in T1D treatment in recent years. The medication targets the underlying autoimmune process that destroys insulin-producing cells, potentially slowing or even halting disease progression. Early results suggest it may be particularly effective when administered early in the disease course."
            },
            meta: {
              published: "January 2025",
              phase: "Phase 2 Clinical Trials",
              status: "Recruiting",
              priority: "HIGH"
            },
            link: "#"
          },
          {
            id: "fda-fast-track-2024",
            badge: "NEW",
            title: "FDA Fast-Tracks Novel Beta Cell Regeneration Therapy",
            summary: "The FDA has granted Fast Track designation to a revolutionary therapy that uses stem cell technology to regenerate insulin-producing beta cells in Type 1 Diabetes patients. This could be the first treatment to actually restore natural insulin production.",
            details: {
              heading: "ðŸ’¡ Why This Matters:",
              content: "Unlike current treatments that manage symptoms, this therapy aims to address the root cause by replacing the destroyed beta cells. The Fast Track designation means the FDA recognizes the potential for significant improvement over existing treatments and will expedite the review process."
            },
            meta: {
              published: "December 2024",
              phase: "Phase 1/2 Trials",
              status: "Active",
              priority: "HIGH"
            },
            link: "#"
          },
          {
            id: "ai-closed-loop-2025",
            badge: "BREAKTHROUGH",
            title: "AI-Powered Closed-Loop System Achieves 95% Time in Range",
            summary: "A new artificial intelligence-powered insulin delivery system has achieved remarkable results in clinical trials, keeping blood glucose levels in the target range 95% of the time - a significant improvement over current systems.",
            details: {
              heading: "ðŸ¤– Technical Innovation:",
              content: "This AI system learns from individual patient patterns and continuously adapts insulin delivery in real-time. The 95% time-in-range result represents a major leap forward in diabetes management technology, potentially reducing complications and improving quality of life."
            },
            meta: {
              published: "January 2025",
              phase: "Phase 3 Trials",
              status: "Completed",
              priority: "MEDIUM"
            },
            link: "#"
          }
        ];

        // Display breaking news
        const breakingNewsList = document.getElementById('breakingNewsList');
        if (breakingNews.length === 0) {
          breakingNewsList.innerHTML = '<div class="loading">No breaking news at this time. Check back soon!</div>';
        } else {
          breakingNewsList.innerHTML = breakingNews.map(news => `
            <div class="breaking-item">
              <div class="breaking-badge">${news.badge}</div>
              <h3 class="breaking-title">${news.title}</h3>
              <p class="breaking-summary">${news.summary}</p>
              <div class="breaking-details">
                <h4>${news.details.heading}</h4>
                <p>${news.details.content}</p>
              </div>
              <div class="breaking-meta">
                <span>Published: ${news.meta.published}</span>
                <span>Phase: ${news.meta.phase}</span>
                <span>Status: ${news.meta.status}</span>
                <span>Priority: ${news.meta.priority}</span>
              </div>
              <a href="${news.link}" class="breaking-link">Read Full Report â†’</a>
            </div>
          `).join('');
        }
      } catch (error) {
        console.error('Error loading breaking news:', error);
        document.getElementById('breakingNewsList').innerHTML = '<div class="loading">Error loading breaking news. Please refresh.</div>';
      }
    }

    // Function to add new breaking news (for easy updates)
    function addBreakingNews(newsItem) {
      const breakingNewsList = document.getElementById('breakingNewsList');
      const newsElement = document.createElement('div');
      newsElement.className = 'breaking-item';
      newsElement.innerHTML = `
        <div class="breaking-badge">${newsItem.badge}</div>
        <h3 class="breaking-title">${newsItem.title}</h3>
        <p class="breaking-summary">${newsItem.summary}</p>
        <div class="breaking-details">
          <h4>${newsItem.details.heading}</h4>
          <p>${newsItem.details.content}</p>
        </div>
        <div class="breaking-meta">
          <span>Published: ${newsItem.meta.published}</span>
          <span>Phase: ${newsItem.meta.phase}</span>
          <span>Status: ${newsItem.meta.status}</span>
          <span>Priority: ${newsItem.meta.priority}</span>
        </div>
        <a href="${newsItem.link}" class="breaking-link">Read Full Report â†’</a>
      `;
      breakingNewsList.insertBefore(newsElement, breakingNewsList.firstChild);
    }

    // Load all content on page load
    loadReports();
    loadTrials();
    loadBreakingNewsTeaser();
  </script>
</body>
</html>
